Crinetics Pharmaceuticals, Inc. (CRNX)
84.95
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Crinetics Pharmaceuticals Cash from Investing (Quarterly) : 26.29M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 26.29M |
| March 31, 2026 | -252.36M |
| December 31, 2025 | 57.11M |
| September 30, 2025 | 164.81M |
| June 30, 2025 | 37.95M |
| March 31, 2025 | -85.96M |
| December 31, 2024 | -542.09M |
| September 30, 2024 | 20.60M |
| June 30, 2024 | -53.64M |
| March 31, 2024 | 0.309M |
| December 31, 2023 | -87.31M |
| September 30, 2023 | -193.30M |
| June 30, 2023 | 31.44M |
| March 31, 2023 | 48.76M |
| December 31, 2022 | 36.85M |
| September 30, 2022 | 6.822M |
| June 30, 2022 | -174.27M |
| March 31, 2022 | -43.38M |
| Date | Value |
|---|---|
| December 31, 2021 | -101.80M |
| September 30, 2021 | -7.025M |
| June 30, 2021 | 19.84M |
| March 31, 2021 | 32.50M |
| December 31, 2020 | -8.892M |
| September 30, 2020 | -24.83M |
| June 30, 2020 | 17.60M |
| March 31, 2020 | 16.34M |
| December 31, 2019 | -12.82M |
| September 30, 2019 | 20.45M |
| June 30, 2019 | 9.443M |
| March 31, 2019 | 24.60M |
| December 31, 2018 | -118.68M |
| September 30, 2018 | -0.251M |
| June 30, 2018 | -0.469M |
| March 31, 2018 | -0.057M |
| December 31, 2017 | -0.231M |
| September 30, 2017 | -0.018M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | -45.80M |
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Bristol Myers Squibb Co. | -1.614B |
| Corcept Therapeutics, Inc. | -29.24M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -94.19M |
| Cash from Financing (Quarterly) | 8.925M |
| Free Cash Flow | -425.18M |
| Free Cash Flow Per Share (Quarterly) | -0.8973 |
| Free Cash Flow to Equity (Quarterly) | -94.05M |
| Free Cash Flow to Firm (Quarterly) | -94.71M |
| Free Cash Flow Yield | -5.02% |